卵巢功能去势联合芳香化酶抑制剂治疗绝经前转移性乳腺癌的临床观察

Clinical Observation on Ovarian Function Castration Combined Aromatase Inhibitor Therapy for Premenopausal Metastatic Breast Cancer

目的：探讨使用卵巢功能去势联合芳香化酶抑制剂来曲唑对绝经前转移性乳腺癌的临床治疗效果及安全性,以提高绝经前转移性乳腺癌的治疗效果。方法：将2010年9月~2012年5月我院收治绝经前转移性乳腺癌患者共86例为研究对象。随机分为两组,对照组患者使用他莫替芬治疗,实验组患者使用卵巢功能去势戈舍瑞林联合芳香化酶抑制剂来曲唑治疗,对比观察两组患者的治疗效果、治疗过程中不良反应等。结果：实验组患者经过临床治疗后,其临床获益率更高,无病进展生存时间更长,与对照组患者比较差异明显,P〈0.05,差异有统计学意义;43例实验组患者治疗期间的不良反应主要为潮热、恶心、乏力、皮疹等,均为I度和II度之间,患者耐受性较好。结论：使用卵巢功能去势联合芳香化酶抑制剂对绝经前转移性乳腺癌患者做治疗具有较好的效果,患者临床获益高,生存时间长,且耐受性好。

Objective： To investigate the therapeutic effects and safety of ovarian castration combined aromatase inhibitor letrozole treatment for premenopausal metastatic breast cancer, improve the clinical efficacy for premenopausal metastatic breast cancer.Methods： From September 2010 to May 2012 eighty-six patients with premenopausal metastatic breast cancer in our hospital were enrolled in this study.All the cases were randomly assigned into the control arm which received routine tamoxifen treatment and the trial arm receiving goserelin for ovarian castration combined with aromatase inhibitor letrozole.The therapeutic effects and adverse reactions during the treatment in the two arms were compared.Results： After all treatment courses completed, the clinical benefit rate and disease-progressionfree survival in the trial arm were preferable to the control arm, and the differences were statistically significant（P〈0.05）.In the 43 patients of the trail arm, main adverse reactions were hot flashes, nausea, fatigue and skin rash from degree I to II.The patients were tolerated.Conclusion： The ovarian castration combined aromatase inhibitors treatment for premenopausal metastatic breast cancer has a high clinical benefit for patient, plus longer survival time and well tolerance.